Ion Beam Applications SA IBAB.BR · Stock Open Ion Beam Applications SA in new tab
Ion Beam Applications SA Analysis (IBAB.BR)
Is Ion Beam Applications SA a good investment? Ion Beam Applications SA (IBAB.BR) is currently trading at 15.22 EUR. Market analysts have a consensus price target of 17.63 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 18.93. This valuation is generally in line with the broader market.
Earnings Schedule: Ion Beam Applications SA is expected to release its next earnings report on March 25, 2027. The market consensus estimate for Forward EPS is 1.10.
For income investors, Ion Beam Applications SA pays a dividend yield of 1.64%. With a payout ratio of 29%, the dividend appears sustainable.
Investor FAQ
Does Ion Beam Applications SA pay a dividend?
Yes, it pays an annual dividend of 0.25 EUR (1.64% yield).
What asset class is Ion Beam Applications SA?
Ion Beam Applications SA is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be March 25, 2027. The company currently has a trailing EPS of 0.82.
Company Profile
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.28 EUR
|
| July 1, 2027 (estimated) | 0.2763 |
| ▸2026 |
0.25 EUR
|
| July 1, 2026 | 0.2500 |
| ▸2025 |
0.24 EUR
|
| July 1, 2025 | 0.2400 |
| ▸2024 |
0.12 EUR
|
| June 24, 2024 | 0.1190 |
| ▸2023 |
0.15 EUR
|
| July 3, 2023 | 0.1470 |
| ▸2022 |
0.13 EUR
|
| July 1, 2022 | 0.1330 |
| ▸2021 |
0.14 EUR
|
| June 23, 2021 | 0.1400 |
| ▸2020 |
0.05 EUR
|
| July 1, 2020 | 0.0532 |
| ▸2017 |
0.29 EUR
|
| May 16, 2017 | 0.2900 |
| ▸2016 |
1.39 EUR
|
| May 17, 2016 | 1.3900 |
| ▸2015 |
0.17 EUR
|
| May 19, 2015 | 0.1700 |
| ▸2011 |
0.15 EUR
|
| May 18, 2011 | 0.1500 |
| ▸2009 |
0.08 EUR
|
| May 20, 2009 | 0.0800 |
| ▸2008 |
0.17 EUR
|
| June 2, 2008 | 0.1700 |
| ▸2005 |
3.10 EUR
|
| Feb. 1, 2005 | 3.1000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Ion Beam Applications SA | Jul 01, 2026 | Paid | 0.25 EUR |
Community Discussion